Fineline Cube

Follow:
14422 Articles
WuXi Biologics to Sell Irish Vaccine Assets to MSD for USD 500 Million
CompanyDeals

WuXi Biologics to Sell Irish Vaccine Assets to MSD for USD 500 Million

Junshi Biosciences' Loqtorzi Gains Regular Approval for Melanoma Treatment in China
CompanyDrug

Junshi Biosciences’ Loqtorzi Gains Regular Approval for Melanoma Treatment in China

Simcere Zaiming's SIM0505 Receives NMPA Approval for Clinical Trials in Advanced Solid Tumors
CompanyDrug

Simcere Zaiming’s SIM0505 Receives NMPA Approval for Clinical Trials in Advanced Solid Tumors

NMPA Releases 88th Batch of Reference Drugs for Generic Quality Consistency Evaluation
Policy / Regulatory

NMPA Releases 88th Batch of Reference Drugs for Generic Quality Consistency Evaluation

Huahui Health's HH-003 Gains Priority Review Status for Chronic Hepatitis D Treatment
CompanyDrug

Huahui Health’s HH-003 Gains Priority Review Status for Chronic Hepatitis D Treatment

WuXi Biologics and Candid Therapeutics Ink Global Research Agreement for Trispecific T-cell Engager
CompanyDrug

WuXi Biologics and Candid Therapeutics Ink Global Research Agreement for Trispecific T-cell Engager

Amoytop Biotech's Pegfilgrastim Gains NMPA Approval for Preeclampsia Clinical Trials
CompanyDrug

Amoytop Biotech’s Pegfilgrastim Gains NMPA Approval for Preeclampsia Clinical Trials

Hengrui Pharmaceuticals Files IPO Prospectus in Hong Kong Amid Record Deal-Making
CompanyDeals

Hengrui Pharmaceuticals Files IPO Prospectus in Hong Kong Amid Record Deal-Making

Changchun BCHT Partners with Baosight Software for Biopharmaceutical Digitization
CompanyDeals

Changchun BCHT Partners with Baosight Software for Biopharmaceutical Digitization

CDE Announces 90th Batch of Reference Preparations for GQCE
Policy / Regulatory

CDE Announces 90th Batch of Reference Preparations for GQCE

Solasia Pharma Licenses Episil to GeneScience for Greater China Region
CompanyDeals

Solasia Pharma Licenses Episil to GeneScience for Greater China Region

Alebund Pharmaceuticals Completes Series C Financing to Advance Kidney Disease Pipelines
CompanyDeals

Alebund Pharmaceuticals Completes Series C Financing to Advance Kidney Disease Pipelines